In last trading session, NovoCure Ltd (NASDAQ:NVCR) saw 1.95 million shares changing hands with its beta currently measuring 0.68. Company’s recent per share price level of $18.65 trading at -$0.14 or -0.75% at ring of the bell on the day assigns it a market valuation of $2.01B. That closing price of NVCR’s stock is at a discount of -122.57% from its 52-week high price of $41.51 and is indicating a premium of 41.72% from its 52-week low price of $10.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.08 million shares which gives us an average trading volume of 1.48 million if we extend that period to 3-months.
For NovoCure Ltd (NVCR), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.14. Splitting up the data highlights that, out of 5 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NovoCure Ltd (NASDAQ:NVCR) trade information
Upright in the red during last session for losing -0.75%, in the last five days NVCR remained trading in the green while hitting it’s week-highest on Tuesday, 07/23/24 when the stock touched $18.65 price level, adding 3.77% to its value on the day. NovoCure Ltd’s shares saw a change of 24.92% in year-to-date performance and have moved 0.92% in past 5-day. NovoCure Ltd (NASDAQ:NVCR) showed a performance of 3.38% in past 30-days. Number of shares sold short was 7.02 million shares which calculate 3.44 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 46.71% to its current value. Analysts have been projecting 14.5 as a low price target for the stock while placing it at a high target of 200. It follows that stock’s current price would jump 22.25% in reaching the projected high whereas dropping to the targeted low would mean a gain of 22.25% for stock’s current value.
NovoCure Ltd (NVCR) estimates and forecasts
Statistics highlight that NovoCure Ltd is scoring comparatively higher than the scores of other players of the relevant industry. The company added 33.17% of value to its shares in past 6 months, showing an annual growth rate of 18.46% while that of industry is 15.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -22.97% during past 5 years.
NVCR Dividends
NovoCure Ltd is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
NovoCure Ltd (NASDAQ:NVCR)’s Major holders
Insiders are in possession of 9.27% of company’s total shares while institution are holding 85.72 percent of that, with stock having share float percentage of 94.47%. Investors also watch the number of corporate investors in a company very closely, which is 85.72% institutions for NovoCure Ltd that are currently holding shares of the company. FMR LLC is the top institutional holder at NVCR for having 16.06 million shares of worth $251.08 million. And as of 2024-03-31, it was holding 15.099 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.02 million shares on 2024-03-31. The number of shares represents firm’s hold over 9.4218 of outstanding shares, having a total worth of $156.67 million.
